These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

693 related articles for article (PubMed ID: 34392600)

  • 1. The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
    Zhang L; Wang L; Jiang X
    Dermatol Ther; 2021 Sep; 34(5):e15098. PubMed ID: 34392600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
    Zhang L; Du D; Wang L; Guo L; Jiang X
    J Dermatol; 2021 Dec; 48(12):1877-1883. PubMed ID: 34487567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term efficacy and safety of biologics and Janus kinase inhibitors for patients with atopic dermatitis: A systematic review and meta-analysis.
    Chen Q; Cui L; Hu Y; Chen Z; Gao Y; Shi Y
    Heliyon; 2023 Nov; 9(11):e22014. PubMed ID: 38034798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
    Li C; Sun X; Zhao K; Meng F; Li L; Mu Z; Han X
    Dermatology; 2022; 238(4):725-735. PubMed ID: 34455413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
    Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis.
    Alves C; Penedones A; Mendes D; Batel Marques F
    Eur J Clin Pharmacol; 2022 Dec; 78(12):1923-1933. PubMed ID: 36207461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
    Arora CJ; Khattak FA; Yousafzai MT; Ibitoye BM; Shumack S
    Dermatol Ther; 2020 Jul; 33(4):e13685. PubMed ID: 32463149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis.
    Sedeh FB; Henning MAS; Jemec GBE; Ibler KS
    Acta Derm Venereol; 2022 Aug; 102():adv00764. PubMed ID: 35818735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study.
    Landis MN; Arya M; Smith S; Draelos Z; Usdan L; Tarabar S; Pradhan V; Aggarwal S; Banfield C; Peeva E; Vincent MS; Sikirica V; Xenakis J; Beebe JS
    Br J Dermatol; 2022 Dec; 187(6):878-887. PubMed ID: 35986699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis.
    Drucker AM; Lam M; Elsawi R; Prieto-Merino D; Malek R; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    Br J Dermatol; 2024 Jan; 190(2):184-190. PubMed ID: 37831594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching between JAK Inhibitors in Patients with Atopic Dermatitis: Unanswered Questions in Daily Clinical Practice.
    Mastraftsi S; Bakakis M; Tsiogka A; Afroditi Kleidona I; Gregoriou S
    Acta Dermatovenerol Croat; 2023 Dec; 31(3):162-164. PubMed ID: 38439732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis.
    Lee KP; Plante J; Korte JE; Elston DM
    Skin Health Dis; 2023 Feb; 3(1):e133. PubMed ID: 36751339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors: A Systematic Review and Meta-analysis.
    Chen TL; Lee LL; Huang HK; Chen LY; Loh CH; Chi CC
    JAMA Dermatol; 2022 Nov; 158(11):1254-1261. PubMed ID: 36001310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis - A network meta-analysis.
    Zhang L; Guo L; Wang L; Jiang X
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1937-1946. PubMed ID: 35608188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
    Chu DK; Chu AWL; Rayner DG; Guyatt GH; Yepes-Nuñez JJ; Gomez-Escobar L; Pérez-Herrera LC; Díaz Martinez JP; Brignardello-Petersen R; Sadeghirad B; Wong MM; Ceccacci R; Zhao IX; Basmaji J; MacDonald M; Chu X; Islam N; Gao Y; Izcovich A; Asiniwasis RN; Boguniewicz M; De Benedetto A; Capozza K; Chen L; Ellison K; Frazier WT; Greenhawt M; Huynh J; LeBovidge J; Lio PA; Martin SA; O'Brien M; Ong PY; Silverberg JI; Spergel JM; Smith Begolka W; Wang J; Wheeler KE; Gardner DD; Schneider L
    J Allergy Clin Immunol; 2023 Dec; 152(6):1493-1519. PubMed ID: 37678572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
    Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of risk of incident acne and treatment with systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis.
    Sun C; Su Z; Zeng YP
    Inflamm Res; 2023 Sep; 72(9):1861-1871. PubMed ID: 37707560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.